Cellosaurus logo
expasy logo

Cellosaurus SUP-B15 (CVCL_0103)

[Text version]
Cell line name SUP-B15
Synonyms Sup-B15; SUPB-15; SUPB15; SupB15; SupB15W; SupB15WT
Accession CVCL_0103
Resource Identification Initiative To cite this cell line use: SUP-B15 (RRID:CVCL_0103)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Population: Caucasian.
Doubling time: ~18 hours (PubMed=3162827); ~60 hours (DSMZ=ACC-389).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: HLA class I peptidome analysis by proteomics.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
Sequence variations
HLA typing Source: PubMed=26589293
Class I
HLA-AA*03:01,11:01
HLA-BB*51:02,52:01
HLA-CC*12:02,14:02
Genome ancestry Source: PubMed=30894373

Origin% genome
African0
Native American0.5
East Asian, North0.25
East Asian, South0.2
South Asian1.01
European, North70.33
European, South27.71
Disease Childhood B acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2) BCR-ABL1 (NCIt: C68659)
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) (ORDO: Orphanet_585909)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_S642 (SUP-B15/RI)CVCL_DR65 (SupB15RT)
Originate from same individual CVCL_A308 ! SUP-B13
Sex of cell Male
Age at sampling 9Y
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP; DSMZ; PubMed=25877200; PubMed=30879952

Markers:
AmelogeninX,Y
CSF1PO11,12
D2S133820,23
D3S135815,16
D5S81812,13
D7S82010,11
D8S117911,14
D13S3178,14
D16S53911,12
D18S5114
D19S43313,15
D21S1128,31
FGA19,20
Penta D9,12
Penta E21
TH016,9.3
TPOX8,9
vWA15,17

Run an STR similarity search on this cell line
Publications

PubMed=3162827
Naumovski L., Morgan R., Hecht F., Link M.P., Glader B.E., Smith S.D.
Philadelphia chromosome-positive acute lymphoblastic leukemia cell lines without classical breakpoint cluster region rearrangement.
Cancer Res. 48:2876-2879(1988)

PubMed=7630190
Zhou M.-X., Gu L.-B., James C.D., He J., Yeager A.M., Smith S.D., Findley H.W.
Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene in cell lines established from children with acute lymphoblastic leukemia.
Leukemia 9:1159-1161(1995)

PubMed=7888679; DOI=10.1182/blood.V85.6.1608.bloodjournal8561608
Zhou M.-X., Yeager A.M., Smith S.D., Findley H.W.
Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene.
Blood 85:1608-1614(1995)

PubMed=8704231; DOI=10.1182/blood.V88.3.785.785
Kim D.-H., Moldwin R.L., Vignon C., Bohlander S.K., Suto Y., Giordano L., Gupta R., Fears S., Nucifora G., Rowley J.D., Smith S.D.
TEL-AML1 translocations with TEL and CDKN2 inactivation in acute lymphoblastic leukemia cell lines.
Blood 88:785-794(1996)

PubMed=9067587; DOI=10.1038/sj.leu.2400571
Uphoff C.C., MacLeod R.A.F., Denkmann S.A., Golub T.R., Borkhardt A., Janssen J.W.G., Drexler H.G.
Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in human early B-lineage leukemia cell lines.
Leukemia 11:441-447(1997)

PubMed=9108419; DOI=10.1182/blood.V89.8.2986
Findley H.W., Gu L.-B., Yeager A.M., Zhou M.-X.
Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia.
Blood 89:2986-2993(1997)

PubMed=9823951; DOI=10.1038/sj.leu.2401198
Zhou M.-X., Gu L.-B., Yeager A.M., Findley H.W.
Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression.
Leukemia 12:1756-1763(1998)

PubMed=10071072; DOI=10.1016/s0145-2126(98)00171-4
Drexler H.G., MacLeod R.A.F., Uphoff C.C.
Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.
Leuk. Res. 23:207-215(1999)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=15843827; DOI=10.1038/sj.leu.2403749
Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J., Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M., Fioretos T.
Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.
Leukemia 19:1042-1050(2005)

PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25576301; DOI=10.1074/mcp.M114.042812
Bassani-Sternberg M., Pletscher-Frankild S., Jensen L.J., Mann M.
Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation.
Mol. Cell. Proteomics 14:658-673(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30285677; DOI=10.1186/s12885-018-4840-5
Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P.
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
BMC Cancer 18:940.1-940.13(2018)

PubMed=30629668; DOI=10.1371/journal.pone.0210404
Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.
Screening human cell lines for viral infections applying RNA-Seq data analysis.
PLoS ONE 14:E0210404-E0210404(2019)

PubMed=30879952; DOI=10.1016/j.ymthe.2019.02.014
Kailayangiri S., Altvater B., Lesch S., Balbach S.T., Gottlich C., Kuhnemundt J., Mikesch J.-H., Schelhaas S., Jamitzky S., Meltzer J., Farwick N., Greune L., Fluegge M., Kerl K., Lode H.N., Siebert N., Muller I., Walles H., Hartmann W., Rossig C.
EZH2 inhibition in Ewing sarcoma upregulates GD2 expression for targeting with gene-modified T cells.
Mol. Ther. 27:933-946(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=35354797; DOI=10.1038/s41467-022-29224-5
Leo I.R., Aswad L., Stahl M., Kunold E., Post F., Erkers T., Struyf N., Mermelekas G., Joshi R.N., Gracia-Villacampa E., Ostling P., Kallioniemi O.-P., Pokrovskaja Tamm K., Siavelis I., Lehtio J., Vesterlund M., Jafari R.
Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines.
Nat. Commun. 13:1691.1-1691.19(2022)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) AddexBio; C0003019/4892 - Discontinued
ATCC; CRL-1929
BCRJ; 0229 - Discontinued
DSMZ; ACC-389
IZSLER; BS TCL 238
Cell line databases/resources CLO; CLO_0009161
cancercelllines; CVCL_0103
CCRID; 3101HUMTCHu190
Cell_Model_Passport; SIDM01176
Cosmic-CLP; 1247871
DepMap; ACH-000059
DSMZCellDive; ACC-389
LINCS_LDP; LCL-1041
Biological sample resources BioSample; SAMN03473114
BioSample; SAMN10987666
Chemistry resources ChEMBL-Cells; CHEMBL4295393
ChEMBL-Targets; CHEMBL4296498
GDSC; 1247871
PharmacoDB; SUPB15_1518_2019
PubChem_Cell_line; CVCL_0103
Encyclopedic resources Wikidata; Q54970859
Experimental variables resources EFO; EFO_0006763
Gene expression databases ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM236806
GEO; GSM236842
GEO; GSM887658
GEO; GSM888750
GEO; GSM1374913
GEO; GSM1670490
GEO; GSM5137745
GEO; GSM5137767
Polymorphism and mutation databases Cosmic; 1012120
Cosmic; 1130245
Cosmic; 1498420
Cosmic; 1524821
Cosmic; 1630017
Cosmic; 2491077
IARC_TP53; 30174
LiGeA; CCLE_418
Progenetix; CVCL_0103
Proteomic databases PRIDE; PXD000394
PRIDE; PXD023662
PRIDE; PXD030304
Sequence databases EGA; EGAS00001000610
EGA; EGAS00001000978
EGA; EGAS00001002554
Entry history
Entry creation04-Apr-2012
Last entry update05-Oct-2023
Version number40